Purpose: Fecal occult blood testing is recommended as first-line screening to detect colorectal cancer (CRC). We evaluated markers and marker combinations in serum as an alternative to improve the detection of CRC.
The early detection of colorectal cancer (CRC) significantly improves the prognosis of patients and is a key factor to reduce the mortality from CRC (1) . Recently, the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology have issued joint guidelines for CRC screening to include well-known procedures as guaiac-based fecal occult blood testing (FOBT) and fecal immunochemical testing (FIT), colonoscopy, sigmoidoscopy, and double-contrast barium enema, but also 2 more recent methods, computer tomography colonography and fecal DNA testing (2) . The guidelines of the U.S. Preventive Services Task Force have also been updated but do not include the latter 2 methods (3).
Serum-based, minimally invasive markers would be highly attractive for CRC screening as they could easily be integrated in any health checkup without the need of additional stool sampling. Although numerous biomarkers are under evaluation for the detection of CRC from serum, none of them has sufficient sensitivity and specificity to be considered in the current guidelines (4) . Carcinoembryonic antigen (CEA) and carbohydrate antigens, for example, CA19-9 have been assessed more intensely but with varying results depending on the study design and the study population (4) . Recently, nucleic acid-based markers, including RNA, DNA, and epigenetic modifications, have come into focus (5) (6) (7) (8) (9) (10) (11) (12) . Although some of the markers, for example, a panel of 5 RNA markers (7) or hypomethylated SEPT-9 DNA (11), showed good sensitivities of 88% and 68%, the respective specificities of 69% and 89% will burden a high number of patients with a false-positive result if used for screening. In a more recent study, the sensitivity and specificity of SEPT-9 were confirmed with 73% and 91%, respectively (12) . Guanylyl cyclase C (GCC) RNA (5) and L6 RNA (6) showed high sensitivity with 74% and 79% at 95% and 100% specificity but have not yet been extensively validated.
Using an ELISA format, we evaluated new tumor markers together with established markers. The clinical performance of these markers was assessed as stand-alone markers or in marker combinations with the intention not to replace but to initiate a follow-up colonoscopy for a definite diagnosis.
Materials and Methods

Study design and sample collection
Blood and stool samples were collected prospectively in 2 European multicenter studies that have previously been described (13) . The respective research protocols were reviewed and approved by the appropriate ethics committees and written informed consent was obtained from patients prior to sample collection.
All blood samples were collected before surgery or colonoscopy according to the standard operating procedures in standardized collection tubes that were provided to the participating centers. Whole blood was collected in SMonovette tubes without gel separator (Sarstedt). The blood samples were centrifuged, serum was collected, dispensed into cryotubes, and stored at À70 C. After arrival in our laboratory, the samples were thawed, aliquoted, and stored again at À70 C. Clinical samples from both multicenter studies were compiled for the evaluation (Table 1 and Fig. 1) . A: Control cohort with 266 patients. Patients with adenoma or inflammatory bowel diseases were excluded. Gastrointestinal (GI)-healthy controls were only preselected to be free of any bowel disease. No other exclusion criteria, for example, chronic diseases, were applied to controls. B: Advanced adenoma cohort containing 143 patients with any lesion containing high-grade dysplasia, villous, or tubovillous architecture, or tubular adenoma with at least 1 cm. C: CRC cohort with 301 CRC patients from both studies. Samples from 141 patients with benign gastrointestinal conditions were collected in both studies (Table 1) . Samples from patients with other cancer diagnosis were collected in surgical units. Patients with comorbidities commonly found in a screening population were not excluded from the study. The comorbidities of the control and cancer cohort are given in Supplementary Table S1 .
Immunoassays
The ELISA tests were measured blinded in duplicate in serum at Roche Diagnostics GmbH. Laboratory personnel were unaware of clinical data. To exclude lot-to-lot variance a single-assay lot was used for all samples wherever feasible and controls were run. For each assay, a sample aliquot was thawed and residual volume was discarded after testing. The tumor markers of the Elecsys test menu from Roche Diagnostics were measured: CEA, CA15-3, CA125, CA19-9, CA72-4, CYFRA 21-1, ferritin, NSE, AFP, and HCG þ b. Commercial ELISA kits were obtained for TIMP-1 and HGF (R&D Systems), interleukin-6 (Roche Diagnostics GmbH), and interleukin-8 (BD Biosciences).
For all other biomarkers, prototype ELISA kits were developed using standard assay procedures as described previously for nicotinamide N-methyltransferase (NNMT; ref. 14), PSME3 (15) , and S100A12 (16) . The technical performance of the prototype ELISA kits was validated to meet the following specifications (not shown): intraassay CV and interassay CV (<15%), linearity of dilution (AE10% of theoretical value), and analyte recovery in spiked samples (100% AE 20%). Although the intraassay CV was specified to be less than 15%, it was found to be routinely less than 10% for double determinations of patient samples. The sensitivity of the assays was adjusted to detect base levels in healthy subjects, with the exception of anti-p53, because healthy subjects are expected to be autoantibody negative.
For the seprase ELISA (Swiss-Prot accession: Q12884), serum samples were diluted at 0.05% in an antibody mix in incubation buffer (40 mmol/L phosphate buffer pH7.4, 10 mmol/L EDTA, 0.1% Tween 20, 2 mg/mL BSA, 1 mg/mL bovine IgG) containing monoclonal anti-seprase antibodies D8 and D28 0.375 mg/mL each, labeled with digoxigenin and biotin, respectively (17) . After 2 hours at room temperature, aliquots were transferred onto a strepavidincoated microtiter plate and incubated for 1 hour. After washing (TBS, pH 7.4, 0.05% Tween 20), 100 mL of antidigoxigenin peroxidase conjugate (30 mU/mL) were added for 1 hour, washed, and then followed by tetramethylbenzidine (TMB) substrate for color development. The reaction was stopped after 1 hour with 2N sulfuric acid and the absorbance was measured at 450/620 nm. The seprase concentrations were calculated in arbitrary units, using a serial dilution of a human serum containing a high seprase concentration.
Osteopontin (OPN) was measured using an ELISA based on rabbit polyclonal antibodies against peptides covering amino acids 211-228 and 288-304 of human OPN (SwissProt accession: P10451). Biotinylated anti-OPN (288-304) antibodies were used to capture and digoxygenylated anti-OPN (211-228) antibodies to detect the analyte. Samples
Translational Relevance
The current practice of colorectal cancer (CRC) screening is based on stool assays and imaging methods, e.g. colonoscopy. To preselect patients, fecal occult blood testing or fecal immunochemical testing is routinely used prior to colonoscopy and only patients with a positive test result are referred to a specialist. Although these assays are useful screening tools, patient compliance with stool-based assays tends to be low. Serum-based assays for the early detection of CRC are highly attractive, as they could be integrated into any regular health checkup without the need for additional stool sampling, thereby increasing acceptance among patients. The combination of serum markers presented in this study intends to trigger a follow-up colonoscopy for a final diagnosis. It could be an alternative approach for the early detection of CRC.
were diluted 1:100 into an antibody mix in incubation buffer (s. seprase assay) containing 2.2 mg/mL of each of the anti-OPN antibodies. After 1 hour, 100 mL aliquots were transferred to a streptavidin-coated microtiter plate, incubated for another hour, and finally processed as described above. The assay was calibrated in pmol/L, using a serial dilution in equine serum of an OPN fragment, amino acids 211-314, expressed in Escherichia coli.
ASC (Swiss-Prot accession: Q9ULZ3) and Serpin B5 (Swiss-Prot accession: P36952) were measured with ELISA assays, using rabbit polyclonal antibodies raised against full-length recombinant protein from E. coli. In addition, an antibody against amino acids 331-347 of Serpin B5 was raised and used as capture antibody. Capture antibodies were biotinylated, whereas the detection antibodies were digoxigenylated. The respective sandwich-forming antibodies were diluted in incubation buffer (s. seprase assay) at a concentration of 1 mg/mL each, 100 mL of this mix were added to 20 mL standard or serum and incubated in a streptavidin-coated microtiter plate. The plates were washed and processed as above. The assays were calibrated against a serial dilution of recombinant protein from E. coli in equine serum.
For the detection of anti-p53 auto-antibodies, 2 biotinylated peptides representing amino acids 11-35 and 41-60 of human p53 (Swiss-Prot accession: P04637) in PBS, 0.05% Tween 20 at 50 ng/mL were immobilized on a streptavidin-coated microtiter plate with 100 mL/well. After washing 100 mL of serum samples diluted 1:50 in PBS/ 0.05% Tween 20 were added and incubated for 120 minutes at 30 C. After washing, bound IgG was labeled with 25 mU/mL anti-human IgG-peroxidaxe conjugate. Subsequent to washing, bound conjugate was detected as in the seprase assay. The assay was calibrated using a highly positive serum with 1,000 U/mL corresponding to an optical density of 3.0 at 450 nm. Fecal assays, hemoglobin-haptoglobin (Hb-Hpt) complex, and S100A12, were conducted as reported (13) .
Statistical analysis
A rule for serum biomarkers was determined on a training-test-design based on Monte Carlo Cross Validation (MCCV). A special type of penalized logistic regression, Lasso-regression, was used, both as a classification algorithm and as a selection procedure for a subset of relevant biomarkers (18, 19) .
Two different biomarker rules were established for different subsets of the study population, one including all CRC patients and controls (algorithm I) and a second rule for the same collective but without CRC stage IV (algorithm II) as classified according to the staging of the "International Union against Cancer" (UICC). The software "R" was used for rule generation.
The results were assessed by receiver operating characteristic (ROC) analysis and by determining the sensitivity at a preset specificity of 95% or 98%, respectively (20) .
Data were first divided randomly into training (67%) and test sets (33%) and stratified by age, gender, survey panel, and site. Then an MCCV with 100 runs was executed on the training set. The medians of the sensitivities and specificities over all 100 runs of MCCV are reported as training results. They were used to determine an optimized set of parameters for the Lasso-regression. The optimized Lasso-regression was applied to the training set for generating a final diagnostic rule and determining the final thresholds at the specificities of 95% and 98%. This rule was then applied to the independent test set. By application of the final rule to the test set, the test results were obtained (ROC curves, sensitivities, specificities) for the assessment of the diagnostic potential of the biomarkers. The final rule was also applied to the adenoma panel and to the individual CRC stages. Because of sample numbers of the individual cancer stages, the analysis by stages included samples from training and test sets. 
Results
Marker candidates
Marker candidates were identified using different methods covering proteomics methods, Affymetrix studies, literature search, and through collaborations (not shown). Sixty biomarkers, including 10 established tumor markers from the Elecsys system (Roche Diagnostics), were considered as potential biomarkers. Of these, 52 were evaluated in 50 CRC patients and 50 apparently healthy controls, which were not used later on in the enlarged sample panel for the multivariate analysis (not shown). Finally, 22 biomarkers were assessed in an extensive patient panel that included screening relevant controls (Table 1) .
Univariate analysis
When the biomarkers were measured in the patient collectives described in Table 1 , the median concentrations of the markers differed by a factor of less than 3. Although most markers gave increased concentrations in CRC patients versus controls, the concentrations of ferritin and surprisingly of seprase were decreased (Table 2) . When we prevalidated seprase with Western blots of tumor and adjacent healthy tissue from CRC patients, we detected increased expression in cancer tissue (not shown) as has been described by others (21) . However, when we measured seprase in serum, we found decreased concentrations in cancer patients with a median of 26.1 versus 37.6 U/mL.
In a clinical setting, the sensitivity of a biomarker is most relevant. Therefore, the cutoff was set to achieve a specificity of 95% in controls that reflected the screening situation. The control cohort was age matched with a median age of 62.0 years to the CRC patients and included relevant gastrointestinal diseases. As no exclusion criteria besides inflammatory bowel diseases or adenoma were applied to the control collective, patients with comorbidities commonly found in people, older than 50 years, for example, hypertension or diabetes, were included (Supplementary Table S1 ). When the specificity was set to 95%, none of the markers was sufficiently sensitive to be a screening marker on its own. The established tumor marker CEA gave the highest sensitivity with 43.9%, followed by the novel marker seprase (42.4%), CYFRA 21-1 (35.5%), and OPN (30.2%). Ferritin and anti-p53 were less sensitive with 23.9% and 20.0%, respectively. The tumor markers AFP, CA15-3, and HCG þ b reached sensitivities below 10% and were excluded from further evaluation. None of the markers selected for a marker combination (s. multivariate analysis) detected advanced adenomas with sufficient sensitivity (Table 3) .
When analyzed by tumor stages, seprase was at least 10% more sensitive in early stages than CEA or CYFRA 21-1 (Table 3 ) in stage I even 22.8% compared with these 2 markers. In the screening relevant stages 0-III seprase reached a sensitivity of 45.4% and a very similar sensitivity of 42.4% including all stages. CEA and CYFRA 21-1 gave a comparable sensitivity only when all stages were considered as these markers have an excellent sensitivity in stage IV patients. However, they were less sensitive in stages 0-III with 30.9% and 22.3%, respectively.
Multivariate analysis
To improve the clinical performance, we evaluated marker combinations by the application of Lasso-regression including either all stages (algorithm I) or only the more screening relevant stages 0-III (algorithm II). Focusing on stages 0-III (Table 4) , the following markers were selected with Lasso-regression: CEA, ferritin, and seprase in each of 100 runs of the MCCV in the training set. OPN was selected in 99, and CYFRA 21-1 and anti-p53 in 68 runs, respectively. Although additional markers were selected by the algorithm, a marked drop in the selection frequency from 68 to 26 runs or less beyond these 6 markers was evident ( Supplementary Fig. S2 ). To estimate the stability of the algorithm, the marker combination selected in the training set was validated in an independent test set ( Table 4 ). The .7) n.a. combination of the 6 top markers significantly improved the sensitivity of CRC detection. For the evaluation of cancer patients with stages 0-III, the sensitivity at 95% specificity increased from 45.4% to 68.0% in the test set as compared with the best single marker seprase (Tables 3 and 4) . When all tumor stages were included, the sensitivity improved to 69.6% versus 43.9% for CEA. A detailed analysis by tumor stages revealed a remarkable increase of the sensitivity at 95% specificity. The sensitivities for the stages I-III improved from 36.0%, 49.3%, and 51.3%, respectively, with the best single marker to 44.0%, 75.4%, and 71.4% with the marker combination. Because of sample numbers, patients from the training set were included in this analysis, which might lead to an increased sensitivity in the individual stages. In patients with adenomas the sensitivity increased to 22.7% but was still insufficient.
For a screening marker, that will trigger a follow-up colonoscopy for the final diagnosis, a higher specificity would reduce the number of unwarranted colonoscopies, thereby reducing the burden of false-positive results for the patients. Hence, we investigated the sensitivity at 98% specificity. Although algorithm I lost 9.6% and algorithm II 8.4% in the training set, the sensitivity was still high with 61.2% (all stages) and 56.2% (stages 0-III), that translated in the test set to a sensitivity of 58.7% and 53.3%, respectively. For the individual cancer stages, the sensitivity of the serum marker combination was at 98% specificity comparable with or higher than the sensitivities found for the individual markers in the univariate analysis at 95% specificity (Table 3) .
We applied algorithm II (stages 0-III) to CRC patients from the screening situation, (study I, Fig. 1 ). On the basis of n ¼ 12, for which values for all 6 markers were available, the sensitivity was 66.7% (90% CI, 34.9-90.1) and 41.7% (90% CI, 15.2-72.3) at 95% and 98% specificity, respectively. However, these results are preliminary and have to be taken with care due to the low sample number. Clearly, the sensitivity of the marker combination needs to be tested in an independent screening study to fully assess its potential.
The specificity of the CRC marker combination versus disease controls, including benign gastrointestinal diseases (Table 5) , was assessed by applying the cutoff derived from controls at 98% specificity. The specificity of the combination was 60.3% against all diseases with variations against specific subgroups. When the specificity was assessed in patients suffering from other cancer types, applying again the cutoff derived from controls at 98% specificity, the specificity was 75.0% (Table 5 ). It ranged from excellent 97.0% in prostate cancer to 46.7% in lung cancer.
We compared the serum marker combination with fecal Hb-Hpt and to a combination of Hb-Hpt with S100A12 (13) . In a subset including 75 CRC patients and 234 controls from the total study collective, with matched serum and stool samples, the respective assays were run in parallel. In these patients, the sensitivity of the serum marker combination was higher than in the complete patient collective (Table 4) . When compared with the fecal methods, the serum marker combination seemed to be as sensitive as Hb-Hpt with 82.4% versus 81.8% and 68.9% versus 72.7%, but it was less sensitive than the fecal marker combination that gave a sensitivity of 90.9% and 79.2% at 95% and 98% specificity, respectively.
Discussion
Biomarker-based CRC screening currently applies the detection of occult fecal blood, using either FOBT or FIT, though these methods have limitations in sensitivity and/ or specificity. We had recently evaluated the potential of fecal marker combinations to improve the sensitivity of CRC screening (13) . A combination of Hb-Hpt, S100A12, and, depending on the specificity level, TIMP-1 resulted in an increased sensitivity. Although such a combination of fecal markers is useful, serum markers could be integrated in a health checkup more easily having a significant impact on CRC screening due to improved patient compliance. In contrast to stool samples, microbial contamination or interference by an ill-defined matrix is not an issue with serum, implicating a more reproducible recovery of analytes. Unfortunately, current serum markers lack sufficient sensitivity or specificity to be used as stand-alone screening markers (4) . In consequence, marker combinations have been explored to solve this dilemma; for example, for CRC, 2 studies showed an increase of the AUC from 0.75, with the best single marker to 0.80 and 0.81 with combinations of CEA þ CA72-4 or CEA þ CA72-4 þ CA19-9 (22, 23) , respectively. When we applied the principles from our recent study to serum markers and reduced the number of potential marker candidates in a stepwise procedure, we identified a combination of 6 markers that detects CRC in serum with high sensitivity: seprase, OPN, anti-p53 autoantibodies, ferritin, CEA, and CYFRA 21-1.
An increased expression of seprase in cancer including CRC has been shown and our Western blot results from tissue confirmed this (21, (24) (25) (26) . However, most surprisingly the concentrations in serum seemed to be reduced instead when we used an in-house ELISA to discriminate CRC from controls. As seprase is a membrane bound protein, this might be due to the processing that could differentially lead to soluble seprase or to a loss of an epitope of the specific antibodies used in our assay. Alternatively, isoforms might be considered. However, only an additional, intracellular isoform has so far been reported, which does not explain the discrepant results in tissue and serum (27) . The mechanism behind the serum concentrations is therefore currently unclear. Although the concentrations found in serum are in opposition to the expression in tissue, we found a higher sensitivity in early CRC stages as has been shown by Henry et al., using semiquantitative immunohistochemistry (25) .
OPN has been linked to various cancer types, for example, breast, colon, prostate, or lung cancer (28) (29) (30) (31) . A special focus has been its contribution to tumor cell invasion and metastasis making it a promising tumor marker, although serum concentrations reported by Fedarko et al. were not elevated in colon cancer (31) . The concentrations found in our study were only slightly increased but still contributed to the marker combination.
This also applies to ferritin, for which a lower serum concentration in CRC is correlated with tumor size and blood loss in the bowel (32, 33) . However, it seems that such small differences of CRC versus controls give an insufficient sensitivity for a standalone screening marker (34) .
Anti-p53 autoantibodies in cancer have been investigated in-depth (35, 36) . They lack sensitivity but contribute excellent specificity. Our results confirm findings of M€ uller et al. that a combination of serum anti-p53 with conventional tumor markers increases the sensitivity of cancer detection (37) . For CRC, it increased by 13.5% from 59.7% to 73.2%, when anti-p53-positive status was added to CEA. The high sensitivity in this study might be attributed to the patient collective lacking early stages almost entirely. In contrast, we included a significant number of patients with early-stage disease, as we wanted to assess our marker combination in samples closely representing a screening situation.
The markers selected by Lasso-regression are insufficient diagnostic markers when considered on their own but showed an additive value when combined. CEA is most commonly used in the follow-up of CRC patients after surgery: It is recommended for follow-up but not for diagnosis because of its low sensitivity in early CRC stages in the guidelines of the American Society of Clinical Oncology (38) . In our study, both established tumor markers CEA and CYRA 21-1 showed a good sensitivity in stage IV but only an intermediate performance in early stages. When all 6 markers were combined to analyze stages I-IV, the sensitivity increased notably as compared with the best single marker CEA. The increase was also evident when only stages 0-III were considered. Here, especially seprase contributed to the marker combination, as it had the best performance of all markers in early stages.
The current benchmark for marker-based CRC screening is FIT and any serum marker should at least be as sensitive. The sensitivity of our marker combination in stages 0-III (68.0%) is comparable with a Japanese screening study that reported 65.8% sensitivity, both at 95% specificity (39) . In a subset of our patients, we could confirm this in a side-byside comparison. The sensitivity was slightly higher in these patients than in the total study collective, suggesting that the subset was not strictly representative for all patients. However, the combination of serum markers and FIT, represented in our study by fecal Hb-Hpt, achieved an almost identical performance.
The benefit of an algorithm-based marker combination is an improved sensitivity at high specificity. Simple addition of a positive status for several assays will immediately introduce a loss of specificity. The combination of CEA with anti-p53, as done by M€ uller et al. (37) using a simple "AND" rule for the addition of true positives without adding false positives, is feasible only due to the excellent specificity of anti-p53. The more markers are combined with such a procedure, the more false positives will be included, as the specificity of these markers is usually lower than 100%. As different markers will generate false-positive results in different patients, it will significantly reduce the overall specificity.
The specificity of the serum combination was assessed in disease controls that included benign gastrointestinal conditions and in patients suffering from other cancer types. A specificity of 60.3% in disease controls might be less problematic, as the patients are symptomatic and can easily by identified by a physician in an otherwise nonsymptomatic screening population. Such patients might be referred for colonoscopy without the need of an initial screening assay. On the other hand, a specificity of 75.0% against other cancer types will lead to positive results in colonoscopy-negative patients where no symptoms might be obvious. Although a positive rate of 25% in these patients seems high at first glance, it is also a chance to identify undetected cancer when the follow-up is adjusted to the specific patient situation, for example, lung cancer in smokers or breast cancer in women. In patients in whom no cancer is detected despite a positive test result and negative follow-up procedures, monitoring is an option to control for changes of marker concentrations over time. This could either reveal a false-positive result, or trigger another follow-up if a significant increase is observed. However, only longitudinal studies with high patient numbers can address this issue. Considering the sensitivity of the novel test procedure, the specificity in normal screening participants and the anticipated increased acceptance upon patients as compared with stool testing, we believe that the advantages of a serum screening assay outweigh the risks associated with it.
The primary focus of our study was to evaluate the feasibility of the detection of CRC from serum. Although we included a significant number of patients with early CRC stages, the study population was collected only partially in a screening setting (study I, Fig. 1 ). The validation of the results in a true screening population with increased patient numbers is therefore mandatory.
In conclusion, we describe a combination of 6 serum markers for the early detection of CRC that will initiate a follow-up colonoscopy for a definite diagnosis. The performance of the marker combination is comparable with FIT and might improve the acceptance of CRC screening in the general population, as it can easily be integrated in any health checkup without the need for stool sampling. We are currently validating the algorithm in a multicenter screening study.
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